The first thing I would say is that we are a trading industry. We absolutely depend on trade. We want free trade. We support free trade.
Some of the proposals on the table on pharmaceutical IP are going to restrict trade and restrict our access to foreign markets that are absolutely critical for our companies to continue to invest here.
We are concerned about some of the pharmaceutical IP provisions. We support a Canada-European trade agreement strongly, but we would like to see those provisions amended or taken out.